biostudies-literatureImam FNIA NIH HHSNINDS NIH HHSJohnson and JohnsonWellcome Trust2556-2566https://www.ebi.ac.uk/biostudies/studies/S-EPMC12353841biostudies-literatureUnknown31(8)More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. Despite this growing burden, there are currently no cures, and treatment options remain limited due to disease heterogeneity, prolonged preclinical and prodromal phases, poor understanding of disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is crucial for improving early detection, prognosis, staging and subtyping of these conditions. High-dimensional molecular studies in biofluids ('omics') offer promise for scalable biomarker discovery, but challenges in assembling large, diverse datasets hinder progress. To address this, the Global Neurodegeneration Proteomics Consortium (GNPC)-a public-private partnership-established one of the world's largNature medicineThe Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging.PMC12353841R01 AG057911R01 AG057339U54 NS092089P01 AG019724221854/Z/20/ZU24 AG021886U01 AG079847R01 AG044546P30 AG066444P30 AG019610P30 AG072973U01 AG058922RF1 AG062553U19 AG063911R01 AG061800RF1 AG057470RF1 AG057471P50 AG025688P30 AG062422RF1 AG058501R01 AG056477RF1 AG053303R01 AG053960U01 AG045390R01 AG064227P01 AG026276R01 AG083740R01 AG069453P01 AG003991Suarez-Calvet MVogel JWAbdel-Azim GLiepelt-Scarfone IWyss-Coray TFerrucci LGlobal Neurodegeneration Proteomics Consortium (GNPC)Oh HSBose NReiman EMAnastasi FSlawson CTimmers MVieira FAn LHansson OImam FYang CHohman TJPetersen RCCruchaga CLu LKorologou-Linden RFinney CAMattsson-Carlgren NNho KJohnson ECBDage JLKivimaki MFrasier MLovestone SShvetcov AVilor-Tejedor NRuiz Laza AMiddleton LTTijms BMFarinas ABoxer ALBringmann MSaykin AJBennett DLevey AIRobinson OSmets BAli MPichet Binette ABurns JMWalker KARothstein JDKrish VSaloner RWinchester LMVisser PJfalseThe Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging.More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. Despite this growing burden, there are currently no cures, and treatment options remain limited due to disease heterogeneity, prolonged preclinical and prodromal phases, poor understanding of disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is crucial for improving early detection, prognosis, staging and subtyping of these conditions. High-dimensional molecular studies in biofluids ('omics') offer promise for scalable biomarker discovery, but challenges in assembling large, diverse datasets hinder progress. To address this, the Global Neurodegeneration Proteomics Consortium (GNPC)-a public-private partnership-established one of the world's larg2025-01-01T00:00:00Z2025 Aug2026-05-04T21:56:33.554Z2026-04-07T21:01:47.255ZS-EPMC123538414066504810.1038/s41591-025-03834-0